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Abstract Myocarditis is a challenging diagnosis due to the
extreme diversity of clinical manifestations. The actual inci-
dence of myocarditis is also difficult to determine as
endomyocardial biopsy (EMB), the diagnostic gold standard,
is used infrequently. Nevertheless, in up to 30 % of patients
with biopsy-proven myocarditis, progression to dilated car-
diomyopathy (DCM) can occur and is associated with a poor
prognosis. Recent position statements of the European Society
of Cardiology (ESC) and the American Heart Association
vary widely with regard to indications for performing an
EMB in these patients. This makes decision-making, in par-
ticular for general practitioners (GPs) and regional hospitals,
difficult and unclear. Therefore, we will present a short sum-
mary of the ESC Working Group on Myocardial and Pericar-
dial Diseases statement and our suggestions for GPs and
regional hospitals for the diagnostic approach in patients with
suspected myocarditis.
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Introduction
Myocarditis is a challenging diagnosis due to the extreme
diversity of clinical manifestations [1, 2]. The actual incidence
of myocarditis is difficult to determine as endomyocardial
biopsy (EMB), the diagnostic gold standard [1], is used infre-
quently [2]. The prognosis mainly depends on clinical presen-
tation and EMB findings. Patients presenting with acute myo-
carditis and preserved left ventricular function have a good
prognosis with a high rate of spontaneous improvement with-
out sequelae [3, 4]. Interestingly, patients with fulminant viral
myocarditis and haemodynamic compromise at presentation
appear to have an excellent long-term prognosis and are more
likely to experience complete recovery than patients with acute
myocarditis [4, 5], if patients survive the acute phase supported
by aggressive pharmacological and/or mechanical support.
Nevertheless, in up to 30 % of patients with biopsy-proven
myocarditis, progression to dilated cardiomyopathy (DCM)
can occur and is associated with a poor prognosis [1, 2].
Recently, a 2013 position statement from the European
Society of Cardiology (ESC) Working Group on Myocardial
and Pericardial Diseases [6] recommended heart biopsy to be
performed for all cases of suspected myocarditis, including
most acute and chronic DCM. In contrast, the 2013 American
College of Cardiology Foundation/American Heart Associa-
tion (ACCF/AHA) [7] recommends that EMB should not be
performed in the routine evaluation of patients with heart
failure. How to find the desirable middle between these two
extreme recommendations?
Here, we will present a short summary of the ESCWorking
Group on Myocardial and Pericardial Diseases statement and
our suggestions for general practitioners and regional hospi-
tals for the diagnostic approach in patients with suspected
myocarditis.
Definitions
In line with the statement of the ESCWorking Group, we also
acknowledge that there is some confusion about the terms
DCM, inflammatory cardiomyopathy (CMP) and myocardi-
tis. DCM is a clinical diagnosis based on morphological and
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functional characterisation of the left ventricle [1]; inflamma-
tory CMP is both a histological and a functional diagnosis
characterised by myocarditis in association with systolic and/
or diastolic dysfunction [1]. Myocarditis is an inflammatory
disease of the myocardium diagnosed by established histolog-
ical (Dallas criteria) [8], immunological, and immunohisto-
chemical criteria (>14 leucocytes/mm2 including up to 4
monocytes/mm2 with the presence of CD3 positive T-
lymphocytes >7 cells/mm2) [9]. The histological diagnosis
of myocarditis can be classified according to the type of
inflammatory cell infiltrates: lymphocytic, eosinophilic, poly-
morphic, giant cell myocarditis, and cardiac sarcoidosis. The
ESC task group also recommends the use of subsets of myo-
carditis or inflammatory cardiomyopathy:
& Viral myocarditis : Histological evidence for myocarditis
associated with positive viral polymerase chain reaction
(PCR).
& Autoimmune myocarditis : Histological myocarditis with
negative viral PCR, with or without serum cardiac auto-
antibodies (AABs).
& Viral and immune myocarditis : Histological myocarditis
with positive viral PCR and positive AABs.
Clinical presentation
The clinical manifestations of myocarditis may range from
subclinical disease to fulminant heart failure. A summary of
clinical presentations of patients with biopsy-proven myocar-
ditis is shown in Table 1.
Diagnosis
Several non-invasive diagnostic modalities, including cardiac
magnetic resonance imaging (CMR), can be helpful in the
diagnosis of myocarditis; however we emphasise that EMB
remains the gold standard for the diagnosis of definite myocar-
ditis. Nevertheless, we are aware that performing EMB is not
routine practice in patients with suspected myocarditis. There-
fore, we will present our suggestions regarding the first-line
diagnostic steps in suspected myocarditis patients and when to
refer these patients to a tertiary hospital specialised in EMB.
First-line tests in patients with suspected myocarditis
& Electrocardiogram (ECG)
The ECG is usually abnormal in myocarditis al-
though ECG signs are neither specific nor sensitive
[3]. Diffuse concave (rather than convex in myocardial
ischaemia) ST-T segment elevations without reciprocal
changes and non-specific T-wave changes are suggestive
for myocarditis [10].
Table 1 Clinical presentations of patients with biopsy-proven inflammatory
heart muscle disease
1) Clinical presentations
a) Acute chest pain, percarditic, or pseudo-ischaemic
- Frequently starting with 1-4 weeks of a respiratory or
gastrointestinal infection
- Frequently associated with severe and recurrent symptoms
- In the absence of angiographic evidence of CAD
b) ST/T wave changes
- ST-segment elevation or depression
- T-wave inversions
c) With or without global or regional LV and/or RV dysfunction
on echocardiography or CMR
d) With or without increased TnT/TnI that may have a time
course similar to acute myocardial infarction or a prolonged
and sustained release over several weeks or months
2) New-onset or worsening heart failure in the absence of CAD
and known causes of heart failure
a) New-onset or progressive heart failure over 2 weeks to 3 months
b) Impaired systolic LV and/or RV function, with or without
an increase in wall thickness, with or without dilated LV
and/or RVon echocardiography or CMR
c) Symptoms possibly started after a respiratory or gastrointestinal
infection, or in the peri-partum period
d) Non-specific ECG signs, bundle branch block,
AV block, and/or ventricular arrhythmias
3) Chronic heart failure in the absence of CAD and known
causes of heart failure (see point 2 above)
a) Heart failure symptoms (with recurrent exacerbations)
of >3 months duration
b) Fatigue, palpitation, dyspnoea, atypical chest pain,
arrhythmia in an ambulant patient
c) Impaired systolic LV and/or RV function on
echocardiography or CMR suggestive of DCM
or non-ischaemic cardiomyopathy
d) Non-specific ECG signs, sometimes bundle branch
block and/or ventricular arrhythmias and/or AV-block
4) ‘Life-threatening condition’, in the absence of CAD
and known causes of heart failure comprising
a) Life-threatening arrhythmias and aborted sudden death
b) Cardiogenic shock
c) Severely impaired LV function
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& Echocardiography
Echocardiography is useful to exclude other causes
of heart failure and identify ventricular thrombi; how-
ever, there are no specific echocardiographic features of
myocarditis. As known, segmental or global wall mo-
tion abnormalities can mimic myocardial infarction.
Patients with fulminant myocarditis tend to present with
a non-dilated, thickened, and hypocontractile left ven-
tricle, whereas patients with less acute myocarditis pres-
ent with greater left ventricular dilation and normal wall
thickness. Right ventricular dysfunction is uncommon
but an important predictor of death or cardiac transplan-
tation. Moreover, echocardiography is useful to monitor
changes in cardiac chamber size, wall thickness, ven-
tricular function, and pericardial effusions.
& CMR
State-of-the-art CMR in suspected myocarditis can
localise tissue injury, where different virus types seem
to influence the pattern of myocardial injury [11, 12].
Moreover, CMR can quantitate tissue injury, including
oedema, hyperaemia, and fibrosis, and can support the
diagnosis of myocarditis (Lake Louis criteria) [11, 12].
Based on the Lake Louis criteria, when two or more of
the three criteria are positive, myocardial inflammation
can be predicted with a diagnostic accuracy of 78 %
[11]. Timing is of crucial importance and will depend on
the local availability, expertise and clinical condition of
the patient. It is reasonable to perform CMR prior to
EMB in clinically stable patients and it should not be
performed in life-threatening presentations where EMB
is urgently indicated [13].
& Biomarkers
The sensitivity of cardiac biomarkers of myocardial
injury varies depending on the time from symptom onset
to testing and the cut-off values used [6].
Erythrocyte sedimentation rate and C-reactive pro-
tein levels are often elevated in myocarditis, but they do
not confirm the diagnosis. Cardiac troponins are more
sensitive than creatine kinase levels, however are also
non-specific and when normal do not exclude myocar-
ditis. The same is true for cardiac hormones such as
brain natriuretic peptides, circulating cytokines, and
markers related to extracellular matrix degradation.
Furthermore, viral serology is of limited utility in the
diagnosis of viral myocarditis due to a high prevalence
of circulatory IgG antibodies to cardiotropic viruses in
the general population without viral heart disease. Se-
rum cardiac AABs to various cardiac and muscle-
specific autoantigens can be of diagnostic and prognos-
tic value, however are not commercially available and/
or validated yet.
New proposed criteria for clinically suspected myocarditis
Myocarditis should be suspected in the presence of:
& One or more of the clinical presentations in Table 1, with
or without ancillary features
And
& One or more of the diagnostic criteria from different
categories (I to IV) in Table 2
Or
& When the patient is asymptomatic, 2 or more diagnostic
criteria from different categories (I to IV)
Table 2 Diagnostic criteria for clinically suspected myocarditis
Clinical presentations
- Acute chest pain, percarditic, or pseudo-ischaemic
- New onset (days up to 3 months) or worsening of: dyspnoea
at rest or exercise, and/or fatigue, with or without left and/or
right heart failure signs
- Subacute/chronic (>3 months) or worsening of: dyspnoea at
rest or exercise, and/or fatigue, with or without left and/or
right heart failure signs
- Palpitations, and/or unexplained arrhythmia symptoms and/or
syncope, and/or aborted sudden cardiac death
- Unexplained cardiogenic shock
Diagnostic criteria
1. ECG/Holter/stress test features
Newly abnormal 12 lead ECG and/or Holter and/or stress testing,
any of the following: I to III degree atrioventricular block, or
bundle branch block, ST/T wave change (ST elevation or non ST
elevation, T wave inversion), sinus arrest, ventricular tachycardia
or fibrillation and asystole, atrial fibrillation, reduced R wave
height, intraventricular conduction delay (widened QRS




3. Functional and structural abnormalities on cardiac imaging
(echo/angio/CMR)
New, otherwise unexplained LVand/or RV structure and function
abnormality (including incidental finding in apparently
asymptomatic subjects): regional wall motion or global systolic
or diastolic function abnormality, with or without ventricular
dilatation, with or without increased wall thickness, with or
without pericardial effusion, with or without endocavitary thrombi
4. Tissue characterisation by CMR
Oedema and/or LGE of classical myocarditic pattern9
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Our suggestions include that all patients with clinically
suspected myocarditis should be admitted and considered for
selective coronary angiography, in line with the recommenda-
tions from the ESC Working Group. We differ from the per-
spective of both the ESC and ACCF/AHA regarding the indi-
cation for EMB in patients with suspected myocarditis. We
recommend the golden mean between both statements and use
a more practical approach, particularly for patients presenting
to GPs and/or regional hospitals that often have no access to
state-of-the-art CMR or cannot safely perform EMB. There-
fore, referral for EMB in acute suspected myocarditis patients
(point 1, 2 & 4 in Table 1) is recommended in the case of:
– A life-threatening arrhythmia
– LV dysfunction that does not improve 4–5 days after
onset of symptoms
– LV dysfunction that progressively deteriorates within 4–
5 days after onset of symptoms
– Recurrent myocarditis
Clinical management and outcome
Treatment strategies consist of both conventional therapy and
in case of performing an EMB aetiology-based treatment.
Conventional treatment consists of ACE inhibitors, angioten-
sin II receptor blockers, aldosterone antagonists and beta-
blockers in case of heart failure, according to the ESC guide-
lines for heart failure. In line with these recommendations,
both ACE inhibitors and beta-blockers were independently
associated with LV function recovery in biopsy-proven acute
myocarditis patients with LVEF <50 % [4]. Although there is
a lack of large multicentre trials investigating aetiology-based
treatment, several strategies can be considered based on expert
consensus. These include immunomodulatory therapy (anti-
viral therapy, high-dose intravenous immunoglobulins,
immunoadsorption) or immunosuppressive therapy (in virus-
negative and AAB-positive myocarditis). Serial EMBs are
recommended to evaluate the effect of these aetiology-based
treatment strategies and should be modified accordingly. No-
tably, all recurrences of suspected myocarditis should be treat-
ed as the initial episode, wherein EMB is highly recommend-
ed to investigate a possible cause.
In general, approximately 50 % of patients presenting with
acute myocarditis will spontaneously improve without sequel-
ae within 2–4 weeks; however about 25 % will develop per-
sistent cardiac dysfunction and up to 25–30 % may deteriorate
and either die or progress to end-stage DCM with the need for
heart transplantation (HTx) [1–4]. Concordantly, in a recent
large study of biopsy-proven acute myocarditis patients, the
mortality rate after a mean of 12 years of follow-up was 30 %
and 10 % underwent HTx [4]. Of note, events still occurred
after 8 years of follow-up, particularly in those patients pre-
senting with rhythm disturbances [4]. Finally, EMB evidence
of giant cell myocarditis has the highest 1-year mortality and
HTx rate of ~70 %, with recurrences in up to 25 % in the
allograft heart [14]. Therefore, unless otherwise indicated,
long-term non-invasive cardiological follow-up is recom-
mended in all patients who have experienced myocarditis [6].
Conclusion
The diagnosis of myocarditis remains challenging and the
exact approach varies, as reflected by the different recommen-
dations of both the ESC and ACCF/AHA. Particularly in the
setting of GPs or regional hospitals, timing of referral of a
suspected myocarditis patient to a tertiary hospital remains
unclear. Therefore, we have suggested a more practical ap-
proach for this matter in order to standardise referral of
suspected myocarditis patients and improve patient care. Nev-
ertheless, multicentre randomised trials are needed to provide
further insight in aetiology-based treatments which may im-
prove outcome in these predominantly young patients.
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